TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment

The institution besides confirmed affirmative results from the EMBOLD survey evaluating riluzole for patients with SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs). The affirmative results included a 53% placebo-adjusted simplification successful seizures and nary superior adverse events.

Meanwhile, analysts astatine TD Cowen person reiterated a Buy standing connected the banal and accrued the terms people to $353 from $251. Praxis presented updated Phase 2 RADIANT proceedings information astatine AES 2025 showing its campaigner vormatrigine achieved astir 100% median seizure simplification successful focal onset seizures and astir 80% successful generalized epilepsy, portion interim EMBOLD results revealed relutrigine delivered a 53% placebo-adjusted simplification with continued benefits successful the open-label extension; pursuing these findings, TD Cowen raised its terms people connected Praxis to $353, reflecting assurance successful the company’s epilepsy pipeline.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is simply a clinical-stage biotech institution processing targeted therapies for terrible encephalon disorders similar epilepsy, depression, and question disorders.

While we admit the imaginable of PRAX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.